If a subject experiences a serious adverse event related to the study drug and only minimal information is available, the investigator must submit…

Investigator responsibilities for safety reporting are governed by federal regulations and international guidelines. According to the FDA and ICH GCP, investigators must report all serious adverse events (SAEs) to the sponsor immediately. The lack of complete information does not permit a delay; an initial report must be made promptly to ensure the sponsor can assess the risk and fulfill its own regulatory reporting obligations. Similarly, IRBs/IECs require prompt reporting of any unanticipated problems involving risks to human subjects, which includes related SAEs. The standard practice is to submit the initial, minimal information immediately and provide a detailed follow-up report as more information becomes available.

A. Delaying sponsor notification is a significant regulatory violation; both the sponsor and the IRB/IEC require prompt notification for safety oversight.

C. A five-day window is incorrect. The requirement for an investigator to report an SAE to the sponsor is "immediately" or "promptly," not within a specific multi-day timeframe.

D. A seven-day window is incorrect. This timeline is typically associated with the sponsor's expedited reporting of certain serious and unexpected adverse reactions to regulatory authorities, not the investigator's initial report.

1. U.S. Food and Drug Administration (FDA), Code of Federal Regulations Title 21, Part 312.64(b): "Investigator reports... An investigator shall promptly report to the sponsor any adverse effect that may reasonably be regarded as caused by, or probably caused by, the drug. If the adverse effect is alarming, the investigator shall report the adverse effect immediately."

2. International Council for Harmonisation (ICH) Harmonised Guideline, Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2), Section 4.11.1: "All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports."

3. U.S. Food and Drug Administration (FDA), Code of Federal Regulations Title 21, Part 56.108(b)(1): This regulation requires IRBs to follow written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the FDA of "any unanticipated problems involving risks to human subjects or others." An unexpected SAE related to the study drug qualifies as such a problem.

4. Johns Hopkins University, Institute for Clinical and Translational Research, Investigator Responsibilities – FAQs: "What are the responsibilities of a clinical investigator? ... Reporting adverse events to the IRB and sponsor (as applicable)." The guidance emphasizes adherence to the reporting timelines specified in the protocol and by regulations, which for SAEs is immediate to the sponsor.